Given that each imaging modality has limitations in sensitivity and specificity, multiparametric (e.g., FTV/BPE/ADC) and multimodality (e.g., MRI/PET) approaches will likely be employed to improve the characterization of ER+ breast cancers and the prediction of response to NAC or NET. Here, ESR1 is linked to breast carcinoma.